GHK-Cu Compounding Legal Status: What Patients and Prescribers Need to Know

Does any GHK-Cu product have FDA approval?

No. GHK-Cu is the copper(II) complex of GHK, a tripeptide found in human plasma, saliva and urine [9]. No FDA-approved drug is known to contain it; FDA treats it as a nominated bulk drug substance for compounding rather than an approved medicine [1].

Copper histidinate (Zycubo) is a different compound, and FDA approved it on January 12, 2026 for Menkes disease in children [10]. Compounded drugs in general are not FDA-approved — FDA does not review their safety, effectiveness or quality before they are marketed [11].

Is a copper peptide cream a cosmetic or a drug?

Under the FD&C Act, the answer depends on intended use, not on the ingredient [12]. Cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, which is why copper peptide serums and creams reach the market as cosmetics without an FDA review [12]. Claims that a product treats disease, or affects the structure or function of the body, make it a drug instead [12].

An injectable GHK-Cu product is not a cosmetic, and none is FDA-approved [12].

Can a state-licensed pharmacy compound non-injectable GHK-Cu?

FDA's list carries the entry 'GHK-Cu (except for injectable routes of administration)' in category 1 [1][2]. Category 1 covers substances nominated with enough supporting information for FDA to evaluate and that do not appear on another list [2]. Under its interim policy, FDA generally does not intend to act against compounders using category 1 substances when the conditions in its guidance are met [2].

The listing has moved twice. Non-injectable GHK-Cu was removed from category 1 on April 22, 2026 when the nominations were withdrawn; on May 5, 2026 a nominator clarified that only the injectable route had been withdrawn, and FDA added the non-injectable form back, with the list updated on May 14, 2026 [1][2].

Why is injectable GHK-Cu treated differently?

FDA's page on bulk substances that may present significant safety risks, with content dated 04/22/2026, lists 'GHK-Cu (for injectable routes of administration)' in the table of substances nominated but withdrawn [3]. FDA's stated concern reads: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [3].

Injectable GHK-Cu is not in category 1, and it does not appear in any category on FDA's current list [1].

Has FDA scheduled a vote on the bulks list?

Not yet. FDA has announced that it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether to include GHK-Cu on the pharmacy bulks list. No vote has taken place [1].

Where GHK-Cu is not listed

Two other lists matter for compounding, and GHK-Cu is on neither.

• The October 2026 HHS draft enforcement-discretion policy for peptides names six substances — BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. GHK-Cu is not among them [5].
• GHK-Cu is not on FDA's list of bulk drug substances for outsourcing facilities, updated March 21, 2025 [4].

What human evidence exists?

No dose of GHK-Cu is FDA-approved [1]. The human trials found were small and topical.

A trial in patients with venous stasis ulcers tested a 0.4% tripeptide copper complex cream. In 86 evaluable patients, it was no different from an inert vehicle for ulcer size, while silver sulfadiazine 1% reduced ulcer size [6]. In a randomized trial in which 13 patients completed treatment after CO2 laser resurfacing, computer analysis and blinded evaluators found no significant difference in redness resolution, wrinkles or overall skin quality; the patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [13]. A 2026 systematic review, which retained 64 records, described the human literature as thin and fragmented, with most randomized trials small and run on facial cosmetic creams [14].

What about anti-doping rules?

GHK-Cu is not named on WADA's 2026 Prohibited List or the 2027 List [7][8]. WADA's S0 class covers substances with no approval from any governmental health authority, and the 2027 explanatory notes say that peptides not specifically named may still be prohibited [8]. An athlete's own anti-doping organization is the body that can confirm status for a specific product.